How do COVID-19 vaccines perform against the delta variant? When is FDA approval expected? And is herd immunity really achievable?

Raymond James Biotechnology Analyst Steve Seedhouse, Ph.D., addresses these questions and more in the latest episode of For What It’s Worth. Hear him discuss the latest data around vaccine effectiveness, the transition from pandemic to possible endemic and how COVID-prompted innovation may open the door for the prevention of other illnesses. [Recorded 8/3/21]